CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse

Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a...

Full description

Bibliographic Details
Main Authors: Ali Asghar Baghani, Saman Soleimanpour, Hadi Farsiani, Arman Mosavat, Masoud Yousefi, Zahra Meshkat, Seyed Abdolrahim Rezaee, Saeid Amel Jamehdar, Mohammad Reza Akbari Eydgahi, Hamid Sadeghian, Kiarash Ghazvini
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2017-02-01
Series:Iranian Journal of Basic Medical Sciences
Subjects:
Online Access:http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdf
id doaj-f1dc9a57b69c49769f53a5be133a5e84
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ali Asghar Baghani
Saman Soleimanpour
Hadi Farsiani
Arman Mosavat
Masoud Yousefi
Zahra Meshkat
Seyed Abdolrahim Rezaee
Saeid Amel Jamehdar
Mohammad Reza Akbari Eydgahi
Hamid Sadeghian
Kiarash Ghazvini
spellingShingle Ali Asghar Baghani
Saman Soleimanpour
Hadi Farsiani
Arman Mosavat
Masoud Yousefi
Zahra Meshkat
Seyed Abdolrahim Rezaee
Saeid Amel Jamehdar
Mohammad Reza Akbari Eydgahi
Hamid Sadeghian
Kiarash Ghazvini
CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
Iranian Journal of Basic Medical Sciences
CFP-10
Fcγ2a
Immunogenicity
Mycobacterium tuberculosis
Subunit vaccine
author_facet Ali Asghar Baghani
Saman Soleimanpour
Hadi Farsiani
Arman Mosavat
Masoud Yousefi
Zahra Meshkat
Seyed Abdolrahim Rezaee
Saeid Amel Jamehdar
Mohammad Reza Akbari Eydgahi
Hamid Sadeghian
Kiarash Ghazvini
author_sort Ali Asghar Baghani
title CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
title_short CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
title_full CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
title_fullStr CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
title_full_unstemmed CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
title_sort cfp10: mfcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse
publisher Mashhad University of Medical Sciences
series Iranian Journal of Basic Medical Sciences
issn 2008-3866
2008-3874
publishDate 2017-02-01
description Objective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a fusion protein which consisting or comprising CFP-10 from Mycobacterium tuberculosis and the Fc-domain of  mouse IgG2a was evaluated as a novel subunit vaccine candidate against TB. Materials and Methods: The genetic constructs were cloned in pPICZαA expression vector and recombinant vectors (pPICZαA-CFP-10: Fcγ2a and pPICZαA-CFP-10:His) were transformed into Pichia pastoris. To evaluate the expression of recombinant proteins, SDS-PAGE and immunoblotting were used. The immunogenicity of recombinant proteins, with and without BCG were assessed in BALB/c mice and specific cytokines against recombinant proteins (IFN-γ, IL-12, IL-4, IL-17 and TGF-β) were evaluated. Results: The levels of IFN-γ and IL-12 in mice that received recombinant proteins was higher than the control groups (BCG and PBS). Thus, both recombinant proteins (CFP-10:Fcγ2a and CFP-10:His) could excite good response in Th1-cells. The Fc-tagged protein had a stronger Th1 response with low levels of IL-4, as compared to CFP-10:His. However, the highest level of Th1 response was observed in groups that were vaccinated with BCG (prime) and then received recombinant protein CFP-10: Fcγ2a (booster). Conclusion: The results demonstrated that binding mice Fc-domain to CFP-10 protein can increase the immunogenicity of the subunit vaccine. Further studies, might be able to design and produce a new generation of subunit vaccines based on the Fc-fused immunogen.
topic CFP-10
Fcγ2a
Immunogenicity
Mycobacterium tuberculosis
Subunit vaccine
url http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdf
work_keys_str_mv AT aliasgharbaghani cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT samansoleimanpour cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT hadifarsiani cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT armanmosavat cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT masoudyousefi cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT zahrameshkat cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT seyedabdolrahimrezaee cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT saeidameljamehdar cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT mohammadrezaakbarieydgahi cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT hamidsadeghian cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
AT kiarashghazvini cfp10mfcg2asanoveltuberculosisvaccinecandidateincreasesimmuneresponseinmouse
_version_ 1725434179122888704
spelling doaj-f1dc9a57b69c49769f53a5be133a5e842020-11-25T00:03:24ZengMashhad University of Medical SciencesIranian Journal of Basic Medical Sciences 2008-38662008-38742017-02-0120212213010.22038/ijbms.2017.82318231CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouseAli Asghar Baghani0Saman Soleimanpour1Hadi Farsiani2Arman Mosavat3Masoud Yousefi4Zahra Meshkat5Seyed Abdolrahim Rezaee6Saeid Amel Jamehdar7Mohammad Reza Akbari Eydgahi8Hamid Sadeghian9Kiarash Ghazvini10Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranHIV/AIDS, HTLV and Viral Hepatitis Research Center, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranImmunology Research Center, Inflammation and Inflammatory Diseases Division, Medical school, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranBiotechnology Research Center, Semnan University of Medical Sciences, Semnan, IranOrganic Chemistry, Department of Laboratory Sciences, Mashhad University of Medical Sciences, Mashhad, IranAntimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran|Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranObjective(s): Despite treatment with antibiotics and vaccination with BCG, tuberculosis (TB) is still considered as one of the most important public health problems in the world. Therefore, designing and producing a more effective vaccine against TB seems urgently. In this study, immunogenicity of a fusion protein which consisting or comprising CFP-10 from Mycobacterium tuberculosis and the Fc-domain of  mouse IgG2a was evaluated as a novel subunit vaccine candidate against TB. Materials and Methods: The genetic constructs were cloned in pPICZαA expression vector and recombinant vectors (pPICZαA-CFP-10: Fcγ2a and pPICZαA-CFP-10:His) were transformed into Pichia pastoris. To evaluate the expression of recombinant proteins, SDS-PAGE and immunoblotting were used. The immunogenicity of recombinant proteins, with and without BCG were assessed in BALB/c mice and specific cytokines against recombinant proteins (IFN-γ, IL-12, IL-4, IL-17 and TGF-β) were evaluated. Results: The levels of IFN-γ and IL-12 in mice that received recombinant proteins was higher than the control groups (BCG and PBS). Thus, both recombinant proteins (CFP-10:Fcγ2a and CFP-10:His) could excite good response in Th1-cells. The Fc-tagged protein had a stronger Th1 response with low levels of IL-4, as compared to CFP-10:His. However, the highest level of Th1 response was observed in groups that were vaccinated with BCG (prime) and then received recombinant protein CFP-10: Fcγ2a (booster). Conclusion: The results demonstrated that binding mice Fc-domain to CFP-10 protein can increase the immunogenicity of the subunit vaccine. Further studies, might be able to design and produce a new generation of subunit vaccines based on the Fc-fused immunogen.http://ijbms.mums.ac.ir/article_8231_564b4fba2fca6fd9f17d6ec263b8b059.pdfCFP-10Fcγ2aImmunogenicityMycobacterium tuberculosisSubunit vaccine